Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
Enting
Roelien H
RH
Department of Neurology, University Hospital, Groningen, The Netherlands.
Demopoulos
Alexis
A
DeAngelis
Lisa M
LM
Abrey
Lauren E
LE
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D005134:Eye Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015993:Life Tables; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000628:therapy; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D016879:Salvage Therapy; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D018906:Antineoplastic Agents, Alkylating; D000069283:Rituximab; D003606:Dacarbazine; D000077204:Temozolomide; D008727:Methotrexate